Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma

NCT04339218 | Recruiting Phase 3

• 2 other identifiers: IB 2019-052019-A02477-50
• Study Type: interventional
• Target: 214
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients. This is a multicenter, prospective, open-labeled, 2-arm comparative randomized (1:1) phase III trial. Patients will be randomized with a 1:1 ratio into:

• Arm A (experimental arm): cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.
• Arm B (standard arm): pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization. Pembrolizumab and pemetrexed-carboplatin will be prescribed and administered at the dose recommended by market authorization. Cryoablation treatment should be performed within 6 weeks after the first administration of pembrolizumab. No treatment switching permitted.

Conditions

Lung Adenocarcinoma; Cryotherapy Effect

Keywords

Lung adenocarcinoma, immunotherapy, cryoablation

Outcome Measures

Primary Outcomes (1)

• 1-year overall survival rate

  Overall survival (OS) is defined as the time interval between the date of randomization and the date of death (from any cause). Patients alive will be censored at the date of last follow-up or last patient contact. One-year OS rates will be compared between arms.

  1 year

Secondary Outcomes (26)

• Overall response rate within 6 months as per RECIST v1.1

  throughout the treatment period, an expected average of 6 months

• Overall response rate at 6 months as per RECIST v1.1

  6 months

• Overall response rate as per RECIST v1.1

  throughout the treatment period, an expected average of 1 year

• Duration of overall response

  throughout the treatment period, an expected average of 1 year

• Best overall response rate as per RECIST v1.1

  throughout the treatment period, an expected average of 1 year

Study Arms (2)

Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin

EXPERIMENTAL

Cryoablation of one visceral lesion or bone metastasis excluding liver and sclerotic bone metastases combined with pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.

Device: Cryoablation; Drug: Pembrolizumab; Drug: Pemetrexed; Drug: Carboplatin

Arm pembrolizumab-pemetrexed-carboplatin

ACTIVE COMPARATOR

Combination of Pembrolizumab and pemetrexed-carboplatin prescribed as per market authorization.

Drug: Pembrolizumab; Drug: Pemetrexed; Drug: Carboplatin

Interventions

Cryoablation DEVICE

Cryoablation will be performed by a specialized radiologist, percutaneously, ie "through the skin". The operation is performed under general anesthesia, under the guidance of the scanner. The images from the scanner make it possible to precisely insert and place a needle at the level of the tumor to be treated. Intense cold will be produced by the needle and will destroy the cancer cells by freezing (temperatures of -40 °C). Freezing is localized to the tumor, the rest of the organ will not suffer from the cold. The aftermath of the intervention causes only minimal pain and in most cases does not require pain treatment. As the operation is minimally traumatic, the risk of complications is low. Hospitalization is around twenty-four hours and usual or professional activities can be resumed very quickly.

Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin

Pembrolizumab DRUG

Pembrolizumab will be prescribed and administered at the dose recommended by market authorization.

Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin; Arm pembrolizumab-pemetrexed-carboplatin

Pemetrexed DRUG

Pemetrexed will be prescribed and administered at the dose recommended by market authorization.

Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin; Arm pembrolizumab-pemetrexed-carboplatin

Carboplatin DRUG

Carboplatin will be prescribed and administered at the dose recommended by market authorization.

Arm Cryoablation+pembrolizumab-pemetrexed-carboplatin; Arm pembrolizumab-pemetrexed-carboplatin

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically confirmed non-small lung adenocarcinoma.
• Metastatic disease.
• Treatment with pembrolizumab in combination with pemetrexed-carboplatin as per market authorization.
• At least two target lesions (RECIST1.1), measurable with CT or MRI :
• One target lesion that is amenable for accurate repeated measurements,
• One target lesion (15-40 mm) that is amenable for cryoablation treatment including lung, kidney, adrenal, soft tissue and lytic bone lesions. Liver and sclerotic bone lesions are not allowed to be treated by cryoablation.
• Age ≥ 18.
• Performance status ≤ 2.
• Women of childbearing potential must have a negative serum pregnancy test prior to registration.
• Recovery to grade ≤ 1 from any adverse event derived from previous treatment (excluding alopecia)
• Patients with a social security in compliance with the French law (Loi Jardé).
• Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
• Voluntarily signed and dated written informed consents prior to any study specific procedure.

You may not qualify if:

• Squamous cell tumors and other than adenocarcinoma.
• Prior systemic treatment for advanced non-small cell lung cancer (except adjuvant therapy after complete resection).
• Current or prior use of immunosuppressive medication including any use of oral glucocorticoids, within 21 days before the first dose of pembrolizumab.
• Known contra-indication and/or hypersensitivity to PD1/PD-L1 antagonist and/or cytotoxic therapy.
• Known contra-indication to cryoablation.
• Abnormal coagulation contraindicating biopsy.
• Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma or incidentally discovered good prognosis prostate cancer (T stage \< pT3 and Gleason ≤ 7).
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
• Subjects who participated in an investigational drug or device study within 28 days prior to study entry.
• Known infection with HIV, hepatitis B, or hepatitis C.
• Females who are pregnant or breast-feeding.
• Men or women refusing contraception.
• Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
• Previous enrolment in the present study.
• Individuals deprived of liberty or placed under legal guardianship.

Sponsors & Collaborators

• Institut Bergonié: lead

Study Sites (1)

Institut Bergonié

Bordeaux, Gironde, 33076, France

RECRUITING

MeSH Terms

Conditions

Adenocarcinoma of Lung

Interventions

Cryosurgery; pembrolizumab; Pemetrexed; Carboplatin

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site

Intervention Hierarchy (Ancestors)

Ablation Techniques; Surgical Procedures, Operative; Guanine; Hypoxanthines; Purinones; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Glutamates; Amino Acids, Acidic; Amino Acids; Amino Acids, Peptides, and Proteins; Amino Acids, Dicarboxylic; Coordination Complexes; Organic Chemicals

Study Officials

• Jean PALUSSIERE, MD

  Institut Bergonié

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jean PALUSSIERE, MD

CONTACT

05.56.33.33.47; j.palussiere@bordeaux.unicancer.fr

Simone MATHOULIN-PELISSIER, MD, PhD

CONTACT

s.mathoulin@bordeaux.unicancer.fr

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2020
• First Posted: April 9, 2020
• Study Start: August 28, 2020
• Primary Completion (Estimated): August 27, 2026
• Study Completion (Estimated): August 27, 2028
• Last Updated: January 30, 2026

Record last verified: 2026-01

Locations

FR (1)